Adipokines: The missing link between insulin resistance and obesity

Diabetes and Metabolism

Volumn 34, Issue 1, 2008, Pages 2-11

  Antuna Puente, B ^a,b   Feve, B ^a,c   Fellahi, S ^b   Bastard, J P ^a,b  

^a INSERM   (France)

^b HÔPITAL TENON   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Adipocyte; Adipokines; Diabetes; Macrophage; Metabolic syndrome; Obesity; Review; Visceral adipose tissue

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ANGIOTENSINOGEN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OMENTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL BINDING PROTEIN 4; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASPIN; VISFATIN;

ADIPOCYTE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INFILTRATION; CELL STRESS; CYTOKINE PRODUCTION; DIABETIC OBESITY; ENDOPLASMIC RETICULUM; ENERGY EXPENDITURE; FOOD INTAKE; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LEAN BODY WEIGHT; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE;

ADIPOKINES; ADIPONECTIN; ENDOPLASMIC RETICULUM; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SERUM AMYLOID A PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39149143637     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2007.09.004     Document Type: Review

References (116)

1. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
2. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw 17 (2006) 4-12
3. Lafontan M., and Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights?. Trends Pharmacol Sci 24 (2003) 276-283
4. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
5. Ahima R.S., and Flier J.S. Leptin. Annu Rev Physiol 62 (2000) 413-437
6. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
7. Vidal H., Auboeuf D., De Vos P., Staels B., Riopu J.P., Auwerx J., et al. The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest 98 (1996) 251-255
8. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., et al. Leptin regulates proinflammatory immune responses. FASEB J 12 (1998) 57-65
9. van Dielen F.M., van't Veer C., Schols A.M., Soeters P.B., Buurman W.A., and Greve J.W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 25 (2001) 1759-1766
10. Abdel-Hafez M., Yan H., Kermouni A., and Lau D.C. Adipose-tissue derived cytokines modulate preadipocyte differentiation and leptin production. Int J Obes Relat Metab Disord 26 (2002) S66
11. lau D., Yan H., Abdel-Hafez M., and Kermouni A. Adipokines and the paracrine control of their production in obesity and diabetes. Int J Obes Relat Metab Disord 26 (2002) S111
12. Cooke J.P., and Oka R.K. Does leptin cause vascular disease?. Circulation 106 (2002) 1904-1905
13. Konstantidines S., Schafer K., Koschnick S., and Loskutoff D.J. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism of atherothrombotic disease in obesity. J Clin Invest 108 (2001) 1533-1540
14. Yamagishi S.I., Edelstein D., Du X.L., Kaneda Y., Guzman M., and Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276 (2001) 25096-25100
15. O'Rourke L., Gronning L.M., Yeaman S.J., and Shepherd P.R. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 277 (2002) 42557-42562
16. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., et al. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1686
17. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G.D., Müller C., and Carling D. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 (2002) 339-343
18. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 (2002) 570-578
19. Howard J.K., and Flier J.S. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 17 (2006) 365-371
20. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
21. Koistinen H.A., Bastard J.P., Dusserre E., Ebeling P., Zegari N., Andreelli F., et al. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur J Clin Invest 30 (2000) 302-310
22. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82 (1997) 4196-4200
23. Bhagat K., and Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 96 (1997) 3042-3047
24. Wang P., Ba Z.F., and Chaudry I.H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol Heart Circ Physiol 266 (1994) H2535-H2541
25. Choy J.C., Granville D.J., Hunt D.W., and McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33 (2001) 1673-1690
26. Hermann C., Assmus B., Urbich C., Zeiher A.M., and Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signalling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 402-409
27. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83 (1998) 847-850
28. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 14 (2004) 52273-52282
29. Maachi M., Pieroni L., Bruckert E., Jardel C., Fellahi S., Hainque B., et al. Systemic low grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women. Int J Obes 28 (2004) 993-997
30. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
31. Nonogaki K., Fuller G.M., Fuentes N.L., Moser A.H., Staprans I., Grunfeld C., et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136 (1995) 2143-2149
32. Bastard J.P., Maachi M., Tran Van Nhieu J., Jardel C., Bruckert E., Grimaldi A., et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87 (2002) 2084-2089
33. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
34. Bastard J.P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85 (2000) 3338-3342
35. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., and Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 13 (1995) 369-398
36. Kroder G., Bossenmaier B., Kellerer M., Capp E., Stoyanov B., Muhlhofer A., et al. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signalling. J Clin Invest 97 (1996) 1471-1477
37. Mooney R.A., Senn J., Cameron S., Inamdar N., Boivin L.M., Shang Y., et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276 (2001) 25889-25893
38. Lagathu C., Bastard J.P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic Interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by Rosiglitazone. Biochem Biophys Res Commun 311 (2003) 372-379
39. Rieusset J., Bouzakri K., Chevillotte E., Ricard N., Jacquet D., Bastard J.P., et al. SOCS (Suppressor Of Cytokine Signaling)-3 expression and insulin resistance in skeletal muscle of obese and Type 2 diabetic patients. Diabetes 53 (2004) 2232-2241
40. Pedersen B.K., and Fischer C.P. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 10 (2007) 265-271
41. Geiger P.C., Hancock C., Wright D.C., Han D.H., and Holloszy J.O. IL-6 increases muscle insulin sensitivity only at superphysiological levels. Am J Physiol Endocrinol Metab 292 (2007) E1842-E1846
42. Glund S., Deshmukh A., Long Y.C., Moller T., Koistinen H.A., Caidahl K., et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56 (2007) 1630-1637
43. Lihn A.S., Bruun J.M., He G., Pedersen S.B., Jensen P.F., and Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219 (2004) 9-15
44. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Ucchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
45. Kadowaki T., and Yamauchi T. Adiponectin and Adiponectin Receptors. Endocr Rev 26 (2005) 439-451
46. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
47. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
48. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002) 2893-2898
49. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signalling through a camp-dependent pathway. Circulation 102 (2000) 1296-1301
50. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 (2003) E527-E533
51. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
52. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 cause abrogation of adiponectin binding and metabolic actions. Nat Med 13 (2007) 332-339
53. Bjursell M., Ahnmark A., Bohlooly Y.M., William-Olsson L., Rhedin M., Peng X.R., et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56 (2007) 583-593
54. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
55. Kim K.H., Lee K., Moon Y.S., and Sul H.K. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276 (2001) 11252-11256
56. Rajala M.W., Obici S., Scherer P.E., and Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111 (2003) 225-230
57. Banerjee R.R., Rangwala S.M., Shapiro J.S., Rich A.S., Rhoades B., Qi Y., et al. Regulation of fasted blood glucose by resistin. Science 303 (2004) 1195-1198
58. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial activation: further evidence of adipokine-endothelial interaction. Circulation 108 (2003) 736-740
59. Calabro P., Samudio I., Willerson J.T., and Yeh E.T. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110 (2004) 3335-3340
60. Jackson M.B., Osei S.Y., and Ahima R.S. The endocrine role of adipose tissue: focus on adiponectin and resistin. Curr Opin Endocrinol Diab 12 (2005) 163-170
61. Johnson B.D., Kip K.E., Marroquin O.C., Ridker P.M., Kelsey S.F., Shaw L.J., et al. Serum amyloid A as a predictor of coronary heart disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109 (2004) 726-732
62. Leinonen E., Hurt-Camejo E., Wiklund O., Hulten L.M., Hiukka A., and Taskinen M.R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166 (2003) 387-394
63. Lin Y., Rajala M.W., Berger J.P., Moller D.E., Barzilai N., and Scherer P.E. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276 (2001) 42077-42083
64. Poitou C., Viguerie, Cancello R., De Matteis R., Cinti S., Stich V., et al. Serum amyloid A: production by human white adipocytes and regulation by obesity and nutrition. Diabetologia 48 (2005) 519-528
65. Juan-Vague I., Alessi M.C., and Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulinresistance and atherothrombosis. Diabetologia 34 (1991) 457-462
66. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
67. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16 (2000) 192-201
68. Montague C.T., Prins J.B., Sanders L., Zhang J., Sewter C.P., Digby J., et al. Depot and sex-specific differences in human leptin mRNA expression : implications for the control of regional fat distribution. Diabetes 46 (1997) 342-347
69. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
70. Eriksson P., Van Harmelen V., Hoffstedt J., Lundquist P., Vidal H., Stemme V., et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 83 (2000) 545-548
71. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor-1. Diabetes 53 (2004) 336-346
72. Alessi M.C., and Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26 (2006) 2200-2207
73. Dusserre E., Moulin P., and Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 1500 (2000) 88-96
74. Van Harmelen V., Ariapart P., Hoffstedt J., Lundkvist I., Bringman S., and Arner P. Increased adipose angiotensinogen gene expression in human adiposity. Obes Res 8 (2000) 337-341
75. Massiera F., Bloch-Faure M., and Cellier D. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 5 (2001) 2727-2729
76. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
77. Chen M.P., Chung F.M., Chang D.M., Tsai J., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cel colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91 (2006) 295-299
78. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91 (2006) 3165-3170
79. Manco M., Fernandez-Real J., Equitani F., Vendrell J., Valera Mora M.E., Nanni G., et al. Effect of massive weight loss on inflammatory adipocytokines and innate immune system in morbidly obese women. J Clin Endocrinol Metab 92 (2007) 483-490
80. Haider D., Schindler K., Schaller G., Prager G., Wolzt M., and Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduce after gastric banding. J Clin Endocrinol Metab 91 (2006) 1578-1581
81. Varma V., Yao-Borengasser A., Rasouli N., Bodles A., Phanavanh B., Lee M.J., et al. Human visfatin expression relationship to insulin sensitivity, intramyocellular, lipids, and inflammation. J Clin Endocrinol Metab 92 (2007) 666-672
82. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005) 2911-2916
83. Lopez-Bermejo A., Chico-Julia B., Fernandez-Balsells M., Recasens M., Esteve E., Casamitjana R., et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55 (2006) 2871-2875
84. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Russe R., et al. Macropages in human visceral adipose tissue: increased accumulation in obesity and source of resistin and visfatin. Diabetologia 49 (2006) 744-747
85. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol Cell Biol 14 (1994) 1431-1437
86. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113 (2004) 1318-1327
87. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niedderegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178 (2007) 1748-1758
88. Ye S., Simon B., Maloney J., Zambelli-Weiner A., Gao L., Grant A., et al. Pre-B-Cell Colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171 (2005) 361-370
89. Dahl T.B., Yndestad A., Skjelland M., Oie E., Michelsen A., Damas J.K., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115 (2007) 972-980
90. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102 (2005) 10610-10615
91. Kloting N., Berndt J., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339 (2006) 430-436
92. Yang R., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290 (2006) E1253-E1261
93. Schaffler A., Neumeier M., Herfarth H., Furst A., Scholmerich J., and Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732 (2005) 96-102
94. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.H., Yu D.Z., Pray J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56 (2007) 1655-1661
95. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (2005) 356-362
96. Graham T.E., Yang Q., Bluher M., Hammarstedt A., Ciaraldi T.P., Henry R.R., et al. Retinol binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354 (2006) 2552-2563
97. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel L.R., and Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
98. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46 (2005) 2347-2355
99. Clement K., Viguerie N., Poitou C., Carette C., Pelloux V., Curat C.A., et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18 (2004) 1657-1669
100. Cancello R., Henegar C., Viguerie N., Taleb S., Rouault C., Coupaye M., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54 (2005) 2277-2286
101. Curat C.A., Miranville A., Sengenes C., Diehl M., Tonus C., Busse R., et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53 (2004) 1285-1292
102. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance and hepatic steatosis in obesity. J Clin Invest 116 (2006) 1494-1505
103. Lumeng C., Bodzin J., and Saltiel A. Obesity induces phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117 (2007) 175-184
104. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 (2003) 1821-1830
105. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk-beta. Science 293 (2001) 1673-1677
106. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 (2005) 183-190
107. Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
108. Nakatani Y., Kaneto H., Kawamori D., Hatazaki M., Miyatsuka T., Matsouka T.A., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279 (2004) 45803-45809
109. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
110. Gao Z., Zuberi A., Quon M.J., Dong Z., and Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 278 (2003) 24944-24950
111. Shi X., Ding M., Dong Z., Chen F., Ye J., Wang S., et al. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 199 (1999) 93-102
112. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109 (2002) 1321-1326
113. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action and type 2 diabetes. Science 306 (2004) 425-426
114. Nakatani Y., Kaneto H., Kawamori D., Yoshiuchi K., Hatazaki M., Matsuoka T.A., et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 280 (2005) 847-851
115. Ozawa K., Miyazaki M., Matsuhisa M., Takano K., Nakatani Y., Hatazaki M., et al. The endoplasmic reticulum chaperones improves insulin resistance in type 2 diabetes. Diabetes 54 (2005) 657-663
116. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313 (2006) 1137-1140